Phathom director shifts 80,500 shares to trust

Phathom Pharmaceuticals director Asit Parikh reported an internal share transfer involving 80,500 shares of common stock on January 23, 2026.

Accepted by SEC EDGAR 01/27/2026 - 04:38 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Phathom Pharmaceuticals director Asit Parikh reported an internal share transfer involving 80,500 shares of common stock on January 23, 2026. The filing shows these shares moved for no consideration from his direct holdings to a trust for the benefit of his spouse, where he serves as trustee.

After the transactions, Parikh directly holds 50,500 shares and indirectly holds 80,500 shares through the trust. The transferred shares are subject to a lock-up agreement linked to an underwriting agreement dated January 7, 2026, and the trust has agreed to be bound by the same lock-up terms.

Insider Trade Summary

161,000 shares gifted

Gift 2 txns

Insider Parikh Asit

Role Director

Type	Security	Shares	Price	Value
Gift	Common Stock	80,500	$0.00	$0.00
Gift	Common Stock	80,500	$0.00	$0.00

Holdings After Transaction: Common Stock — 50,500 shares (Direct); Common Stock — 80,500 shares (Indirect, by Trust)

Holdings Before and After: Common Stock, 131,000 to 50,500 shares (Direct); Common Stock, 161,000 to 80,500 shares (Indirect, by Trust)

Footnotes (2)

1. F1. Reflects shares transferred for no consideration to a trust for the benefit of the Reporting Person's spouse and for which the Reporting Person serves as trustee.
2. F2. The shares are subject to a lock-up agreement entered into by the Reporting Person in connection with the underwriting agreement dated January 7, 2026 (the Lock-Up Agreement). The trust has agreed in writing to be bound by the same terms described in the Lock-Up Agreement to the extent and for the duration that such terms remain in effect at the time of the transfer.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PHAT director Asit Parikh report on this Form 4?

Director Asit Parikh reported transferring 80,500 shares of Phathom Pharmaceuticals common stock on January 23, 2026. The shares moved for no consideration from his direct ownership into a trust established for the benefit of his spouse, with Parikh serving as trustee.

How did Asit Parikh’s share ownership in PHAT change after the reported transaction?

Following the transactions, Asit Parikh directly owns 50,500 Phathom Pharmaceuticals shares and indirectly owns 80,500 shares through a trust. The filing indicates this was a reallocation between direct and indirect holdings rather than a market sale, with no cash consideration involved.

What is the nature of the trust involved in the PHAT Form 4 transaction?

The 80,500 transferred shares went to a trust created for the benefit of Asit Parikh’s spouse, according to the filing. Parikh serves as trustee of this trust, and the position is reported as indirect ownership of Phathom Pharmaceuticals common stock.

Are the transferred PHAT shares subject to any lock-up or trading restrictions?

Yes. The filing states the 80,500 transferred shares are subject to a lock-up agreement associated with an underwriting agreement dated January 7, 2026. The trust has agreed in writing to be bound by the same lock-up terms for the relevant duration.

What does transaction code "G" mean in Asit Parikh’s PHAT Form 4?

Transaction code "G" on Form 4 identifies the reported movement of 80,500 Phathom Pharmaceuticals shares as a transfer rather than a market purchase or sale. The filing further clarifies it was for no consideration, aligning with a gift or similar non-cash transfer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parikh Asit

(Last) (First) (Middle)

C/O PHATHOM PHARMACEUTICALS, INC.

100 CAMPUS DRIVE, SUITE 102

(Street)

FLORHAM PARK NJ 07932

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Phathom Pharmaceuticals, Inc. [ PHAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/23/2026		G		80,500	D	$0	50,500	D
Common Stock	01/23/2026		G		80,500	A	$0	80,500(1)	I	by Trust(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects shares transferred for no consideration to a trust for the benefit of the Reporting Person's spouse and for which the Reporting Person serves as trustee.

2. The shares are subject to a lock-up agreement entered into by the Reporting Person in connection with the underwriting agreement dated January 7, 2026 (the Lock-Up Agreement). The trust has agreed in writing to be bound by the same terms described in the Lock-Up Agreement to the extent and for the duration that such terms remain in effect at the time of the transfer.

	/s/ Anne Marie Cook, Attorney-in-Fact for Asit Parikh	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.